 |
SK Bioscience |
[Alpha Biz= Reporter Kim Jisun] SK Bioscience's stock surged by 8% on the 27th following the announcement of its acquisition of a top-tier German vaccine contract manufacturing organization (CMO). The stock closed at 53,300 KRW, up by 3,950 KRW (8.00%) from the previous day. During the trading session, it briefly reached 59,200 KRW, marking a 19.96% increase.
The company announced that it had signed an agreement to acquire a controlling stake in IDT Biologika, a German CMO and contract development and manufacturing organization (CDMO) specialist, from the global pharmaceutical and biotech firm Klocke Group.
Founded in 1921, IDT Biologika operates businesses in both Germany and the United States, employing around 1,800 people and valued at approximately 656 billion KRW, according to SK Bioscience.
By acquiring a 60% stake in IDT Biologika, SK Bioscience becomes the company's largest shareholder. The company expects this acquisition to double its revenue, enhance its production capabilities to meet advanced standards, expand its customer network, and establish integrated infrastructure connections in key countries.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
